High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer

• Verfasst von: Nicolay, Nils [VerfasserIn]
• Verfasst von: Rademacher, Johanna [VerfasserIn]
• Verfasst von: Oelmann-Avendano, Jan Tobias [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Huber, Peter E. [VerfasserIn]
• Verfasst von: Lindel, Katja [VerfasserIn]
• Titel: High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer
• Verf.angabe: Nils H. Nicolay, Johanna Rademacher, Jan Oelmann-Avendano, Jürgen Debus, Peter E. Huber, Katja Lindel
• E-Jahr: 2016
• Jahr: 31 May 2016
• Umfang: 9 S.
• Fussnoten: Gesehen am 19.03.2018
• Titel Quelle: Enthalten in: Strahlentherapie und Onkologie
• Ort Quelle: Berlin : Springer Medizin, 1997
• Jahr Quelle: 2016
• Band/Heft Quelle: 192(2016), 7, Seite 458-466
• ISSN Quelle: 1439-099X
• DOI: doi:10.1007/s00066-016-0979-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571187839

Abstract

PurposeThe aim of this work was to evaluate outcomes and toxicities of high dose-rate (HDR) endoluminal brachytherapy in a cohort of esophageal cancer patients.Patients and methodsWe analyzed the records of 36 patients treated with HDR brachytherapy for histologically confirmed esophageal cancer. Brachytherapy was either applied as a boost treatment for definitive treatment regimens or as salvage therapy for recurrent tumors with single doses between 4 and 6 Gy. Survival and toxicities were retrospectively analyzed.ResultsBrachytherapy was performed as initially planned in all but one patient; 18 patients had a complete endoscopic response at the first follow-up examination. Locoregional recurrence was observed in 24 patients after a median time of 3 months; 1‑ and 2‑year recurrence-free survival rates were 51 and 51 % for the patients treated for primary tumors and 11 and 6 % for patients treated for tumor recurrence, respectively. Median overall survival was 18 months; estimated overall survival rates at 1, 2, and 3 years were 63, 50, and 30 % after primary brachytherapy, and 60, 25, and 6 % after recurrence therapy. Adenocarcinoma histology, non-complete remission after treatment, and treatment for recurrent cancers were associated with significantly reduced prognoses. Mild dysphagia was the most common side effect in 17 patients; 8 patients suffered from locoregional grade 3 toxicities, and no grade 4 or 5 toxicities were observed.ConclusionsEndoluminal brachytherapy during the course of esophageal cancer treatment can be safely applied and results in good functional outcomes regarding dysphagia with low rates of severe toxicities.